* DISCLAIMER: All information, including CoinCurb’s, rating is provided merely for informational purposes only. CoinCurb does not provide investment advice.

Injective Protocol

Decentralized Exchange

Injective is the initial front-running resistant, layer-2 exchange protocol that opens the maximum capacity of borderless finance by helping margin trading, derivatives, and futures.

Token Sale
Ended on 20 Oct
$3,600,000 $3,600,000
Website Whitepaper
Social Links
CoinCurb
ICO Drops
ICO Bench
Web Score

Token Sale: Ended on 20 Oct
Ticker:
Token type:
ICO Token Price:
Fundraising Goal:
Total Tokens:
Available for Token Sale:
Min/Max Personal Cap:
Accepts:
Role of Token:
CoinCurb Notes
Not Available
Community Review
Not Available
Information
Follow us on
Daily updates

    TRENDING ico

    Related ICO

    Leave a Reply

    Your email address will not be published.

    four × four =

    INJECTIVE PROTOCOL ICO and INJECTIVE PROTOCOL Token Price

    INJECTIVE PROTOCOL ICO will provide INJECTIVE PROTOCOL’s team with funds for the project’s development. The INJECTIVE PROTOCOL token sale will give the community an opportunity to buy INJECTIVE PROTOCOL tokens.

    This page serves as an aggregation of important data about the INJECTIVE PROTOCOL ICO. Any stated data such as INJECTIVE PROTOCOL ICO price, INJECTIVE PROTOCOL token sale date, INJECTIVE PROTOCOL ICO participation limitations, and/or project-specific details such as INJECTIVE PROTOCOL ICO timeline may be subject to change as per INJECTIVE PROTOCOL ICO team’s discretion. CoinCurb will try to make the effort to keep the INJECTIVE PROTOCOL ICO page updated.

    If the INJECTIVE PROTOCOL ICO establishes new social channels, such as INJECTIVE PROTOCOL ICO Reddit, INJECTIVE PROTOCOL ICO Telegram, INJECTIVE PROTOCOL ICO Twitter, INJECTIVE PROTOCOL ICO Facebook, etc, CoinCurb will try to update the page. Users who are interested in INJECTIVE PROTOCOL ICO should personally consider the reasonability of INJECTIVE PROTOCOL ICO price and INJECTIVE PROTOCOL token sale details.